Education
About Us
Working with TipRanks
Follow Us
Novartis AG (CH:NOVN)
:NOVN
NOVN Stock Chart & Stats
CHF115.60
-CHF1.10(-1.10%)
At close: 4:00 PM EST
CHF115.60
-CHF1.10(-1.10%)
Day’s Range― - ―
52-Week RangeCHF81.10 - CHF116.78
Previous CloseN/A
Volume858.75K
Average Volume (3M)2.71M
Market Cap
CHF220.01B
Enterprise ValueCHF208.96B
Total Cash (Recent Filing)CHF9.75B
Total Debt (Recent Filing)CHF32.02B
Price to Earnings (P/E)18.5
Beta0.97
Next Earnings
Feb 04, 2026EPS Estimate
1.6Next Dividend Ex-DateN/A
Dividend Yield3.18%
Share Statistics
EPS (TTM)1.81
Shares Outstanding2,112,421,900
10 Day Avg. Volume2,438,245
30 Day Avg. Volume2,709,021
Financial Highlights & Ratios
PEG Ratio-0.99
Price to Book (P/B)4.47
Price to Sales (P/S)3.81
P/FCF Ratio14.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF112.33Price Target Upside-2.83% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pipeline And Clinical ReadoutsA slate of mid-to-late stage programs, including remibrutinib in relapsing-remitting multiple sclerosis, could materially shift the product mix and drive upside if upcoming readouts are positive.
Product LaunchesSuccessful launches such as Pluvicto, Scemblix and Leqvio have created new revenue streams that support future top-line growth and reduce reliance on legacy products.
Profitability And Growth TargetsUpgraded mid-term sales ambitions and a commitment to higher operating margins indicate potential for improved profitability if cost efficiencies and launches proceed as planned.
Bears Say
Acquisition-related DilutionEarnings and margin performance may be pressured by dilution and integration costs tied to the Avidity acquisition, weighing on near-term profitability metrics.
Patent ExpirationsPatent expirations on key medicines represent a substantial downside risk as generic entrants could significantly erode established sales.
Valuation And Market SkepticismA neutral valuation stance and cautious feedback from experts on some programs suggest limited upside until clearer clinical or commercial milestones are achieved.
Novartis AG News
NOVN FAQ
What was Novartis AG’s price range in the past 12 months?
Novartis AG lowest stock price was CHF81.10 and its highest was CHF116.78 in the past 12 months.
What is Novartis AG’s market cap?
Novartis AG’s market cap is CHF220.01B.
When is Novartis AG’s upcoming earnings report date?
Novartis AG’s upcoming earnings report date is Feb 04, 2026 which is in 16 days.
How were Novartis AG’s earnings last quarter?
Novartis AG released its earnings results on Oct 28, 2025. The company reported CHF1.806 earnings per share for the quarter, missing the consensus estimate of CHF1.824 by -CHF0.018.
Is Novartis AG overvalued?
According to Wall Street analysts Novartis AG’s price is currently Overvalued.
Does Novartis AG pay dividends?
Novartis AG pays a Annually dividend of CHF3.5 which represents an annual dividend yield of 3.18%. See more information on Novartis AG dividends here
What is Novartis AG’s EPS estimate?
Novartis AG’s EPS estimate is 1.6.
How many shares outstanding does Novartis AG have?
Novartis AG has 2,112,421,900 shares outstanding.
What happened to Novartis AG’s price movement after its last earnings report?
Novartis AG reported an EPS of CHF1.806 in its last earnings report, missing expectations of CHF1.824. Following the earnings report the stock price went down -4.159%.
Which hedge fund is a major shareholder of Novartis AG?
Currently, no hedge funds are holding shares in CH:NOVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
NOVN Stock 12 Month Forecast
Average Price Target
CHF112.33
▼(-2.83% Downside)
Technical Analysis
Options Prices
Currently, No data available
---